Montelukast

Drug Profile

Montelukast

Alternative Names: KIPRES; L-706631; MK-0476; MK-476; Montegen; Montelukast sodium; Romilast; Singulair

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Banyu; CHA University; Kyorin Pharmaceutical; Merck & Co; Merck Sharp & Dohme; Sun Pharmaceutical Industries
  • Class Acetates; Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Exercise-induced asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • No development reported Bronchitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Dec 2015 Launched for Allergic rhinitis in Japan (KIPRES® OD tablets 10mg)
  • 11 Dec 2015 Launched for Asthma in Japan (KIPRES® OD tablets 10mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top